Cell2in is focusing on expanding the business in various ways.
Our platform technologies, products and experiences
will synergize in a collaborative work.

New drug development

We plan to develop human and animal stem cell therapy using the FreSHtracer™ platform and license them out.

High-purity stem cell separation

Separation of stem cells from various donors

Selection of customized stem cell culture media

Culture high-quality stem cells

Selection of disease-targeted stem cells

Stem cells with enhanced anti-inflammatory and immunosuppressive functions

  • Immune-modulatory T, Treg, NK, B cell
  • Anti-apoptotic STC-1, VEGF, HGF, IGF-4
  • Secrete growth factor SCF, M-SCF, KGF, LIF
  • Extracellular matrix remodeling Type II collagen
  • Homing PDGF, IGF-1, chemokine
FreSHtracer™ Application of the self-developed quality control platform

Production of personalized stem cell therapy

  • Intractable asthma
  • Degenerative arthritis
  • Idiopathic pulmonary fibrosis
  • Graft-versus-host disease
  • Multiple sclerosis
  • Animal disease
Collaboration in Korea and overseas

License Out

Clinical phase 1/2a

Technology transfer

Global Big Pharma

Joint large scale clinical trials

Reinvestment in back-up pipelines (expanded indications of cell therapy)